GlassScriptPhysician profile
Melchiore Vernace
NPI 1992765549
$5,779.33
in general payments reported to CMS, 2019-2025
33 companies · $1,190 in 2025
The $1,190 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $605 · 2021: $597 · 2022: $1,081 · 2023: $977 · 2024: $993 · 2025: $1,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,147 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,146.56 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $746.14 | 2020-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $472.95 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $413.57 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $365.51 | 2022-2025 | Tarpeyo |
| Amgen INC. | $337.24 | 2019-2025 | Tavneos, Krystexxa, Uplizna |
| Aurinia Pharma U.S., INC. | $326.55 | 2021-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.90 | 2023-2025 | Jardiance |
| Vifor Pharma, INC. | $242.98 | 2019-2025 | Veltassa |
| Travere Therapeutics, INC. | $221.60 | 2023-2025 | Filspari |
| Ardelyx, INC. | $221.33 | 2023-2025 | Ibsrela |
| Daiichi Sankyo INC. | $214.63 | 2020-2025 | Injectafer |
| Mallinckrodt Hospital Products INC. | $200.69 | 2020-2023 | Acthar |
| Alexion Pharmaceuticals, INC. | $194.95 | 2019-2024 | Ultomiris |
| Biomerieux INC | $180.85 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $178.97 | 2024-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $157.77 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $156.60 | 2022-2025 | Voyxact, Jynarque |
| Nxstage Medical, INC. | $123.46 | 2019-2020 | |
| Fresenius USA Marketing, INC. | $119.18 | 2019-2023 | Velphoro, Korsuva |
| Kyowa Kirin, INC. | $107.42 | 2024-2025 | Crysvita |
| Glaxosmithkline, LLC. | $86.76 | 2020-2023 | |
| Ultragenyx Pharmaceutical INC. | $82.38 | 2021-2022 | |
| Horizon Therapeutics Plc | $73.78 | 2019-2022 | |
| Pharmacosmos Therapeutics INC. | $61.42 | 2022-2025 | Monoferric |
| Amag Pharmaceuticals, INC. | $53.79 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $40.16 | 2021-2023 | Givlaari |
| Lilly USA, LLC | $36.37 | 2025 | Zepbound, Mounjaro |
| Opko Pharmaceuticals, LLC | $35.06 | 2021-2025 | Rayaldee |
| Eisai INC. | $23.72 | 2024 | |
| Mallinckrodt Enterprises LLC | $22.71 | 2019 | |
| Lundbeck LLC | $19.04 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.85 | 2023 | Gattex |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melchiore Vernace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.